NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

about

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

Item

http://www.wikidata.org/entity/Q52323790

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

@en

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

@nl

type

Item

label

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

@en

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

@nl

prefLabel

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

@en

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

@nl

P1476

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.

@en

P2093

Eeva Sliz

http://www.w3.org/2001/XMLSchema#string

Johannes Kettunen

http://www.w3.org/2001/XMLSchema#string

Mika Ala-Korpela

http://www.w3.org/2001/XMLSchema#string

Minna Männikkö

http://www.w3.org/2001/XMLSchema#string

Olli T Raitakari

http://www.w3.org/2001/XMLSchema#string

Pasi Soininen

http://www.w3.org/2001/XMLSchema#string

Sylvain Sebert

http://www.w3.org/2001/XMLSchema#string

P2860

Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC Study

TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content

Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis

Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism

Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review

The genetic architecture of type 2 diabetes

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.

Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.

P304

2214-2223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDY124

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29648650

http://www.w3.org/2001/XMLSchema#string

P932

5985737

http://www.w3.org/2001/XMLSchema#string